AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23062767 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg + Ezetimibe 10/10 mg
Number of subjects: 60
Study 23062767 — intervention group
Group type: COMPARATOR
Intervention: Control group (normolipidemic patients)
Number of subjects: 60
Study 19181399 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated health (SRH) assessment
Number of subjects: 321
Study 18572078 — intervention group
Group type: EXPERIMENTAL
Intervention: Laquinimod 0.6 mg per day
Number of subjects: 306
Study 18572078 — intervention group
Group type: EXPERIMENTAL
Intervention: Laquinimod 0.3 mg per day
Number of subjects: 306
Study 18572078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 16095532 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm for identifying and separating beats from arterial pulse records
Number of subjects: 800
Study 16095532 — intervention group
Group type: COMPARATOR
Intervention: Human operators
Number of subjects: 800
Study 12415583 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 0.5 mg/kg
Number of subjects: 120
Study 12415583 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 1 mg/kg
Number of subjects: 120
Study 12415583 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 3 mg/kg
Number of subjects: 120
Study 12415583 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 5 mg/kg
Number of subjects: 120
Study 12415583 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 10 mg/kg
Number of subjects: 120
Study 12415583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 12802246 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable voice organizer
Number of subjects: 10
Study 12802246 — intervention group
Group type: COMPARATOR
Intervention: No intervention (unrecorded goals)
Number of subjects: 10
Study 9836028 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem-lidocaine combination (0.3 mg.kg‐1 diltiazem plus 1.5 mg.kg‐1 lidocaine)
Number of subjects: 60
Study 9836028 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (0.3 mg.kg‐1)
Number of subjects: 60
Study 9836028 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (1.5 mg.kg‐1)
Number of subjects: 60
Study 7661296 — intervention group
Group type: EXPERIMENTAL
Intervention: Local continuous microwave therapy (CM)
Number of subjects: 141
Study 7661296 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (controls)
Number of subjects: 141
Study 2758362 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low ingestion of hens' egg and cows' milk
Number of subjects: 162
Study 2758362 — intervention group
Group type: COMPARATOR
Intervention: Daily ingestion of one hens' egg and about 11 of cows' milk
Number of subjects: 162
Study 345735 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% timolol maleate administered twice a day for two weeks
Number of subjects: 0
Study 345735 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine hydrochloride (control)
Number of subjects: 0
Study 31012238 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised home-based exergaming for 12 weeks
Number of subjects: 46
Study 31012238 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 46
Study 27874292 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF infusion
Number of subjects: 62
Study 27874292 — intervention group
Group type: COMPARATOR
Intervention: Control group (opted out of G‐CSF)
Number of subjects: 62
Study 27874292 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 26161609 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaseous Ozone (GO) + Fuji Triage Fissure Sealant (FS)
Number of subjects: 60
Study 26161609 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaseous Ozone (GO) + Aegis Fissure Sealant (FS)
Number of subjects: 60
Study 26161609 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaseous Ozone (GO) + Helioseal Fissure Sealant (FS)
Number of subjects: 60
Study 26161609 — intervention group
Group type: COMPARATOR
Intervention: Fuji Triage Fissure Sealant (FS) without Gaseous Ozone (Control)
Number of subjects: 60
Study 23289762 — intervention group
Group type: COMPARATOR
Intervention: Levamisole film-coated tablets
Number of subjects: 100
Study 21041041 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone continuing care with voucher incentives
Number of subjects: 195
Study 21041041 — intervention group
Group type: COMPARATOR
Intervention: Telephone continuing care without voucher incentives
Number of subjects: 195
Study 19051275 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 170
Study 19051275 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational emotive behavioral therapy (REBT)
Number of subjects: 170
Study 19051275 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (Prozac)
Number of subjects: 170
Study 17849636 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (electroacoustic analysis, real-ear measures, hearing aid adjustments based on users' comments)
Number of subjects: 32
Study 17849636 — intervention group
Group type: COMPARATOR
Intervention: Protocol B (Protocol A + speech-in-noise test, loudness discomfort levels, aided loudness)
Number of subjects: 32
Study 17849636 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A
Number of subjects: 32
Study 17849636 — intervention group
Group type: COMPARATOR
Intervention: Protocol B
Number of subjects: 32
Study 15115421 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exercise with pacing
Number of subjects: 61
Study 15115421 — intervention group
Group type: COMPARATOR
Intervention: Relaxation/flexibility therapy
Number of subjects: 61
Study 11293460 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy adaptivity in response to success and failure feedback
Number of subjects: 0
Study 11293460 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasoning ability and working‐memory capacity
Number of subjects: 0
Study 9409351 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (12.5 mg)
Number of subjects: 17
Study 9409351 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (average daily dose of 45 +/- 9.6 mg for 15.5 +/- 8.3 months)
Number of subjects: 17
Study 9409351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 8126300 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide and behavioral management
Number of subjects: 0
Study 8126300 — intervention group
Group type: COMPARATOR
Intervention: Behavioral management
Number of subjects: 0
Study 2960579 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-motor treatment
Number of subjects: 5
Study 2960579 — intervention group
Group type: COMPARATOR
Intervention: Behavior modification
Number of subjects: 5
Study 31985859 — intervention group
Group type: EXPERIMENTAL
Intervention: Living Together With Dementia training programme
Number of subjects: 27
Study 31985859 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 31196678 — intervention group
Group type: EXPERIMENTAL
Intervention: Regenerative cell-based therapy
Number of subjects: 0
Study 31196678 — intervention group
Group type: COMPARATOR
Intervention: Phase 2 trials
Number of subjects: 0
Study 30201691 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated schedule (0, 1, and 2 months)
Number of subjects: 407
Study 30201691 — intervention group
Group type: COMPARATOR
Intervention: Standard schedule (0, 1, and 6 months)
Number of subjects: 407
Study 30201691 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated schedule
Number of subjects: 407
Study 30201691 — intervention group
Group type: COMPARATOR
Intervention: Standard schedule
Number of subjects: 407
Study 27544829 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy for insomnia (CBTi)
Number of subjects: 91
Study 27544829 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 91
Study 25035114 — intervention group
Group type: EXPERIMENTAL
Intervention: Full intervention
Number of subjects: 8
Study 25035114 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial intervention
Number of subjects: 8
Study 25035114 — intervention group
Group type: COMPARATOR
Intervention: Retrospective data
Number of subjects: 8
Study 22938651 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion-cardiovascular magnetic resonance (CMR)
Number of subjects: 533
Study 22938651 — intervention group
Group type: COMPARATOR
Intervention: SPECT
Number of subjects: 533
Study 20531094 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60
Study 20531094 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 60
Study 18689590 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg/d + Formoterol 24 microg/d
Number of subjects: 0
Study 18689590 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 800 microg/d
Number of subjects: 0
Study 18689590 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 microg/d + Formoterol 24 microg/d
Number of subjects: 0
Study 18689590 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 800 microg/d vs Budesonide 200 microg/d + Formoterol 24 microg/d
Number of subjects: 0
Study 16051518 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day (n = 14)
Number of subjects: 38
Study 16051518 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day plus vitamin E 400 IU/day (n = 12)
Number of subjects: 38
Study 16051518 — intervention group
Group type: COMPARATOR
Intervention: No statin or antioxidant treatment (n = 12, controls)
Number of subjects: 38
Study 12919387 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC) at a median dose of 2,400 mg/day
Number of subjects: 76
Study 12919387 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC)
Number of subjects: 76
Study 10929216 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term oral creatine supplementation (20 g.day‐1 for 6 days)
Number of subjects: 23
Study 8848409 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating Neuropeptide Y (NPY)
Number of subjects: 0
Study 8848409 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating Endothelin-1,2 (ET-1,2)
Number of subjects: 0
Study 8848409 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial Natriuretic Peptide (ANP)
Number of subjects: 0
Study 8848409 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline (NA)
Number of subjects: 0
Study 8848409 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Renin Activity (PRA)
Number of subjects: 0
Study 8848409 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone
Number of subjects: 0
Study 1616385 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusive dressings and variable ambient temperature (group I)
Number of subjects: 15
Study 1616385 — intervention group
Group type: EXPERIMENTAL
Intervention: No dressings and variable ambient temperature (group II)
Number of subjects: 15
Study 1616385 — intervention group
Group type: EXPERIMENTAL
Intervention: No dressings and electromagnetic heaters (group III)
Number of subjects: 15
Study 1616385 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (group IV)
Number of subjects: 15
Study 6546371 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg
Number of subjects: 12
Study 6546371 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 200 mg
Number of subjects: 12
Study 6546371 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg
Number of subjects: 12
Study 6546371 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 25 mg
Number of subjects: 12
Study 2425204 — intervention group
Group type: EXPERIMENTAL
Intervention: Galanin infusion at 33.2 pmol/kg/min
Number of subjects: 10
Study 2425204 — intervention group
Group type: EXPERIMENTAL
Intervention: Galanin infusion at 7.8 pmol/kg/min
Number of subjects: 10
Study 2425204 — intervention group
Group type: EXPERIMENTAL
Intervention: Galanin infusion (both doses)
Number of subjects: 10
Study 29698340 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based lecture
Number of subjects: 0
Study 29698340 — intervention group
Group type: COMPARATOR
Intervention: Traditional classroom lecture
Number of subjects: 0
Study 28941361 — intervention group
Group type: COMPARATOR
Intervention: Repeated-mailing outreach
Number of subjects: 29340
Study 28941361 — intervention group
Group type: COMPARATOR
Intervention: Electronic medical record–integrated provider best practice alert (BPA)
Number of subjects: 29340
Study 28941361 — intervention group
Group type: COMPARATOR
Intervention: Direct patient solicitation
Number of subjects: 29340
Study 28881341 — intervention group
Group type: EXPERIMENTAL
Intervention: Height-adjusted total kidney liver volume (hTKLV)
Number of subjects: 309
Study 28881341 — intervention group
Group type: EXPERIMENTAL
Intervention: Height-adjusted total liver volume (hTLV)
Number of subjects: 309
Study 28881341 — intervention group
Group type: EXPERIMENTAL
Intervention: Height-adjusted total kidney volume (hTKV)
Number of subjects: 309
Study 26200111 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach-Avoidance Task (AAT) where participants pulled CS+ pictures towards themselves and pushed CS- pictures away from themselves.
Number of subjects: 2
Study 26200111 — intervention group
Group type: COMPARATOR
Intervention: Control group underwent reversed contingencies in the AAT.
Number of subjects: 2
Study 23982273 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (26 IU intranasal administration)
Number of subjects: 40
Study 23982273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21921425 — intervention group
Group type: EXPERIMENTAL
Intervention: FBRA (fermented brown rice) 21.0 g/day for 2 weeks
Number of subjects: 36
Study 21921425 — intervention group
Group type: COMPARATOR
Intervention: Control food 21.0 g/day for 2 weeks
Number of subjects: 36
Study 18513512 — intervention group
Group type: EXPERIMENTAL
Intervention: Ularitide 15 ng/kg per minute
Number of subjects: 221
Study 18513512 — intervention group
Group type: EXPERIMENTAL
Intervention: Ularitide 30 ng/kg per minute
Number of subjects: 221
Study 16507966 — intervention group
Group type: EXPERIMENTAL
Intervention: Day hospital treatment
Number of subjects: 206
Study 16507966 — intervention group
Group type: COMPARATOR
Intervention: Conventional in-patient care
Number of subjects: 206
Study 11982444 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (30 mg)
Number of subjects: 40
Study 11982444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10680491 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibroin membrane
Number of subjects: 2
Study 10680491 — intervention group
Group type: COMPARATOR
Intervention: 1% SD-Ag cream
Number of subjects: 2
Study 7667822 — intervention group
Group type: EXPERIMENTAL
Intervention: Clexane (enoxaparin)
Number of subjects: 12
Study 7667822 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmin (dalteparin)
Number of subjects: 12
Study 7667822 — intervention group
Group type: EXPERIMENTAL
Intervention: Logiparin (tinzaparin)
Number of subjects: 12
Study 7667822 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UH)
Number of subjects: 12
Study 2652887 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (Tebonin)
Number of subjects: 15
Study 2652887 — intervention group
Group type: COMPARATOR
Intervention: NaCl without drugs stimulating blood flow (Control)
Number of subjects: 15
Study 889672 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous‐oxide‐oxygen technique with neuromuscular blockage
Number of subjects: 138
Study 29497934 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) home visits
Number of subjects: 145
Study 29497934 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 145
Study 25943648 — intervention group
Group type: EXPERIMENTAL
Intervention: Total enterolignans (high urinary concentrations)
Number of subjects: 5179
Study 25943648 — intervention group
Group type: EXPERIMENTAL
Intervention: Total isoflavones (high urinary concentrations)
Number of subjects: 5179
Study 25943648 — intervention group
Group type: EXPERIMENTAL
Intervention: Daidzein (high urinary concentrations)
Number of subjects: 5179
Study 25943648 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterolactone (high urinary concentrations)
Number of subjects: 5179
Study 25131978 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure-lowering treatment
Number of subjects: 67475
Study 22882472 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET); 12 weeks of bicycle exercise training (3 × 40 min/week)
Number of subjects: 61
Study 22882472 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation (NMES); 12 weeks of NMES of quadriceps and calf muscles (frequency 10 Hz, mode '20 s on-20 s off,' intensity 60 mA, 2 × 60 min/day)
Number of subjects: 61
Study 20553355 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole (1% clotrimazole), n = 45
Number of subjects: 96
Study 20553355 — intervention group
Group type: COMPARATOR
Intervention: Nystatin (100,000 IU nystatin/g + 20% zinc oxide), n = 46
Number of subjects: 96
Study 18430210 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ropivacaine 0.75% infusion
Number of subjects: 158
Study 18430210 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 158
Study 16020923 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthos(inert) stent group (carbon-implanted surface stents)
Number of subjects: 140
Study 16020923 — intervention group
Group type: COMPARATOR
Intervention: Arthos stent group (control stents)
Number of subjects: 140
Study 16020923 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthos(inert) stent group
Number of subjects: 140
Study 16020923 — intervention group
Group type: COMPARATOR
Intervention: Arthos stent group
Number of subjects: 140
Study 12545149 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine-6-glucuronide (63 to 112 mg IV bolus, followed by infusion for 1.8 to 6.4 hours)
Number of subjects: 12
Study 12545149 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (26 to 66 mg IV bolus, followed by infusion for 1.8 to 6.4 hours)
Number of subjects: 12
Study 12545149 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not specified)
Number of subjects: 12
Study 10626190 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafamostat mesilate (2 mg/kg/day) administered during and after the operation for 7 days
Number of subjects: 20
Study 10626190 — intervention group
Group type: COMPARATOR
Intervention: Standard post-operative intensive therapies (Control)
Number of subjects: 20
Study 7560231 — intervention group
Group type: EXPERIMENTAL
Intervention: 32% w/w methylene blue in a slow release device at days 0 and 28
Number of subjects: 18
Study 7560231 — intervention group
Group type: COMPARATOR
Intervention: Subgingival debridement
Number of subjects: 18
Study 2042922 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemostagene hemostatic sheets
Number of subjects: 106
Study 2042922 — intervention group
Group type: COMPARATOR
Intervention: Reference collagen sheets
Number of subjects: 106
Study 2042922 — intervention group
Group type: EXPERIMENTAL
Intervention: Both collagen sheets
Number of subjects: 106
Study 6928183 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbital 100 mg
Number of subjects: 50
Study 6928183 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 50
Study 30638151 — intervention group
Group type: COMPARATOR
Intervention: Various cabin control systems for work shifts (randomly assigned vehicles)
Number of subjects: 0
Study 30638151 — intervention group
Group type: COMPARATOR
Intervention: Demographic factors (unmarried, university degree, limited driving experience)
Number of subjects: 0
Study 30194487 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 250
Study 30194487 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 250
Study 26607942 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (500 mg twice daily)
Number of subjects: 14
Study 26607942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 24813598 — intervention group
Group type: EXPERIMENTAL
Intervention: Solomon laser technique
Number of subjects: 151
Study 24813598 — intervention group
Group type: COMPARATOR
Intervention: Standard laser technique
Number of subjects: 151
Study 24813598 — intervention group
Group type: EXPERIMENTAL
Intervention: Solomon laser technique (complete procedure subgroup)
Number of subjects: 151
Study 24813598 — intervention group
Group type: COMPARATOR
Intervention: Standard laser technique (complete procedure subgroup)
Number of subjects: 151
Study 22670856 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous serum (AS) eyedrops diluted at 20%, treatment duration: 2 weeks
Number of subjects: 12
Study 22670856 — intervention group
Group type: COMPARATOR
Intervention: Conventional artificial tears, treatment duration: 2 weeks
Number of subjects: 12
Study 20170821 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 320
Study 20170821 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 320
Study 18818309 — intervention group
Group type: EXPERIMENTAL
Intervention: anti‐CTLA‐4 antibody
Number of subjects: 6
Study 16022747 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (1.5 g daily)
Number of subjects: 74
Study 16022747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 12355995 — intervention group
Group type: COMPARATOR
Intervention: Raloxifen
Number of subjects: 0
Study 10648305 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I - Avoided positive inotropic catecholamines and vasodilators; mechanical ventilation with low tidal volumes < 8 mL/kg, duration of inspiration:expiration = 3:1, peak inspiratory pressures < 18 cm H(2)O
Number of subjects: 47
Study 10648305 — intervention group
Group type: COMPARATOR
Intervention: Group II - Used positive inotropic catecholamines and vasodilators; mechanical ventilation with high tidal volumes (10‐15 mL/kg) and peak inspiratory pressures up to 50 cm H(2)O
Number of subjects: 47
Study 8551788 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte and platelet depletion using blood cell separator CS‐3000, starting immediately after the operation and ending 1 hour after aortic occlusion.
Number of subjects: 42